Advances in immune checkpoint inhibitors therapy for small cell lung cancer

BACKGROUND: As one of the most aggressive neuroendocrine tumors, small cell lung cancer (SCLC) has the most disappointing prognosis of all lung cancers. Although SCLC responds well to initial chemotherapy, the majority of patients experience disease recurrence within one year, and patient survival i...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Longhui, Liang, Yangyueying, Yu, Minghui, Zhao, Lu, Mei, Qingyun, Yu, Yongchao, Wang, Na, Zhang, Dou, Wang, Ziwei, Jia, Yingjie, Kong, Fanming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
REVIEWS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242320/
https://www.ncbi.nlm.nih.gov/pubmed/36880420
http://dx.doi.org/10.1002/cam4.5659

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242320/
https://www.ncbi.nlm.nih.gov/pubmed/36880420
http://dx.doi.org/10.1002/cam4.5659

Ejemplares similares